Skip to main content

Table 2 Circulatory and renal support during the study period

From: Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus

  Day 1 Day 3 Day 7 Day 10 Day 14
ECMO (n = 17) Non-ECMO (n = 18) ECMO (n = 14) Non-ECMO (n = 15) ECMO (n = 14) Non-ECMO (n = 15) ECMO (n = 14) Non-ECMO (n = 15) ECMO (n = 14) Non-ECMO (n = 14)
Use of norepinephrine n (%) 5 (29.4%) 12 (80%)* 8 (57.1%) 11 (73.3%) 7 (50%) 13 (86.7%) 7 (50%) 12 (80%) 5 (35.7%) 13 (92.9%)*
Max. dose (µg kg−1 min−1) 0.08 (0.16) 0.13 (0.25) 0.04 (0.55) 0.15 (0.17)* 0.04 (0.58) 0.43 (0.69)* 0.15 (0.30) 0.06 (0.09) 0.44 (0.58) 0.5 (0.71)
Use of dobutamine n (%) 2 (11.8%) 2 (11.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Max. dose (µg kg−1 min−1) 1.5 (2.21) 5.0 (8.66) NA NA NA NA NA NA NA NA
Use of epinephrine n (%) 0 (0%) NA 0 (0%) NA 0 (0%) 1 (6.7%) 1 (7.1%) NA 1 (5.9%) NA
Max. dose (µg kg−1 min−1) NA NA NA NA NA 1.1 (0.90) 0.10 (0.14) NA 1.5 (0.00) NA
Use of CRRT n (%)a 3 (17.6%) 4 (22.2%) 7 (50%) 6 (40%) 8 (57.1%) 6 (46.7%) 5 (35.7%) 3 (20%) 2 (14.3%) 1 (7.10%)
  1. Results are presented as number (%) or mean (SD)
  2. *P < 0.05 vs. ECMO group
  3. aCRRT continuous renal replacement therapy